[HN Gopher] FDA Approves First Oral Treatment for Postpartum Dep...
       ___________________________________________________________________
        
       FDA Approves First Oral Treatment for Postpartum Depression
        
       Author : gmays
       Score  : 21 points
       Date   : 2023-08-08 20:45 UTC (2 hours ago)
        
 (HTM) web link (www.fda.gov)
 (TXT) w3m dump (www.fda.gov)
        
       | pessimizer wrote:
       | > The primary endpoint of both studies was the change in
       | depressive symptoms using the total score from the 17-item
       | Hamilton depression rating scale (HAMD-17), measured at day 15.
       | Patients in the Zurzuvae groups showed significantly more
       | improvement in their symptoms compared to those in the placebo
       | groups.
       | 
       | Why would you mention the number of items on the scale, but not
       | mention the number of points the drug gained? Is it that
       | professionals normally refer to it as the "17-item Hamilton
       | depression rating scale"?
       | 
       | That they're mentioning the number of points in the scale, but
       | not the number of points gained, makes me wonder if this barely
       | limped into significance under the most favorable conditions.
        
         | duskwuff wrote:
         | > Why would you mention the number of items on the scale, but
         | not mention the number of points the drug gained? Is it that
         | professionals normally refer to it as the "17-item Hamilton
         | depression rating scale"?
         | 
         | Correct. "17-item Hamilton depression rating scale" (or
         | HAMD-17) is the precise name of the scale; "17-item" is
         | required to distinguish it from other variations with different
         | numbers of questions.
         | 
         | The precise improvement in scoring is undoubtedly present in
         | the clinical trial paper, but isn't relevant to a FDA press
         | release about their approval of the drug.
         | 
         | https://dcf.psychiatry.ufl.edu/files/2011/05/HAMILTON-DEPRES...
        
           | ellisv wrote:
           | > The precise improvement in scoring is undoubtedly present
           | in the clinical trial paper, but isn't relevant to a FDA
           | press release about their approval of the drug.
           | 
           | Exactly. If it isn't harmful, it doesn't have to be very
           | helpful -- the effect can be small and significant.
        
         | ellisv wrote:
         | Looks like about 4 points.
         | 
         | [1]
         | https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/21...
        
       | anonymousiam wrote:
       | [flagged]
        
         | otachack wrote:
         | Too late for countless families if you gather all the
         | historical data. That doesn't mean we shouldn't try to curb
         | this.
        
       | 01100011 wrote:
       | https://en.wikipedia.org/wiki/Zuranolone
       | 
       | "An orally active inhibitory pregnane neurosteroid, zuranolone
       | acts as a positive allosteric modulator of the GABAA receptor."
       | 
       | Interesting. I was expecting another SSRI or something similar.
        
         | rabbits_2002 wrote:
         | "positive allosteric modulator of the GABAA receptor", isn't
         | that a benzodiazepine?
         | 
         | edit: nevermind i guess drugs are classified by their chemistry
         | rather than their effects
        
           | trehalose wrote:
           | Drugs can be variously classified by their chemistry and/or
           | by their effects. It's worth noting that GABA-A receptors
           | have multiple allosteric sites, and different chemical
           | classes of PAMs (positive allosteric modulators) may have
           | differences in effects. (There certainly seems to be
           | substantial overlap in effects, of course.)
        
       ___________________________________________________________________
       (page generated 2023-08-08 23:00 UTC)